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Antimicrobial peptides (AMPs) are molecules that act in a wide range of physiological defensive mechanisms developed to counteract
bacteria, fungi, parasites and viruses. Several hundreds of AMPs have been identiﬁed and characterized. These molecules are presently
gaining increasing importance, as a consequence of their remarkable resistance to microorganism adaptation. Carbohydrate-binding
modules (CBMs) are non-catalytic domains that anchor glycoside hydrolases into complex carbohydrates. Clostridium thermocellum pro-
duces a multi-enzyme complex of cellulases and hemicellulases, termed the cellulosome, which is organized by the scaﬀoldin protein
CipA. Binding of the cellulosome to the plant cell wall results from the action of CipA family 3 CBM (CBM3), which presents a high
aﬃnity for crystalline cellulose. Here CipA family 3 CBM was fused to four diﬀerent AMPs using recombinant DNA technology and the
fusion recombinant proteins were expressed at high levels in Escherichia coli cells. CBM3 does not present antibacterial activity and does
not bind to the bacterial surface. However, the four recombinant proteins retained the ability to bind cellulose, suggesting that CBM3 is a
good candidate polypeptide to direct the binding of AMPs into cellulosic supports. A comprehensive characterization of the antimicro-
bial activity of the recombinant fusion proteins is currently under evaluation.
 2008 Elsevier Inc. All rights reserved.
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microbial activities, which vary from bacteria to fungi, par-
asites and viruses. These molecules have been recognized as
an important component of the non-speciﬁc host defense
system and innate immunity of all animal classes, including
insects, amphibians and mammals [1]. Several hundreds of
AMPs have already been identiﬁed and characterized
(http://www.bbcm.units.it/tossi). These molecules repre-
sent very appealing new tools for ﬁghting infection, since
microorganisms do not easily develop resistance mecha-
nisms against their mode of action as it has been described
for other types of antimicrobial compounds. This is prob-1046-5928/$ - see front matter  2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.pep.2008.01.018
* Corresponding author. Fax: +351 253 678 986.
E-mail address: luciliad@deb.uminho.pt (L. Domingues).ably due to the particular capacity of AMPs to bind and
disrupt cellular membranes. It is well recognized that muta-
tions in the genetic information encoding the overall
plasma membrane structure and which may counteract
the action of AMPs are less likely to occur than variations
in the enzyme physiology within a host cell [2].
In early studies involving AMPs, these molecules were
obtained through puriﬁcation from their original hosts or
by chemical synthesis. This, of course, presented many
restrictions to AMPs research mainly in what concerned
the production of detectable quantities of the peptides. In
recent years, many small cationic AMPs have been success-
fully produced using recombinant DNA methods in heter-
ologous hosts [3–6], allowing the puriﬁcation of larger
quantities of the recombinant proteins. It is presently rec-
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techniques will accelerate research on their pharmaceutical
potential and potential clinical application [6]. Many host
cells have been selected for expression of AMPs but Esch-
erichia coli has been established as one of the most popular
recombinant bioreactors due to its fast growth rate and
well-established expression systems [6]. Since AMPs are
usually very small to be produced eﬀectively individually,
many authors aimed to express them in fusion with other
molecules [3,6–8]. Problems concerning low levels of
expression, poor solubility, toxicity for the host cell, prod-
uct proteolysis and poor recovery yields are usually over-
come by the implementation of the fusion technology [9].
Carbohydrate-binding modules (CBMs)1 are non-cata-
lytic domains present in glycoside hydrolases which target
the associated catalytic modules to their substrates, there-
fore potentiating enzyme activity. Based on primary
structure similarity, CBMs have been grouped into 50
sequence-based families (http://afmb.cnrs-mrs.fr/CAZY;
February 2008). Structural studies on representatives of
the majority of CBM families demonstrate that the topol-
ogy of CBM ligand-binding sites complements the confor-
mation of the target polysaccharide. Thus, in Type A
modules, which interact with the ﬂat surfaces of crystalline
polysaccharides, such as cellulose, the binding site com-
prises a planar hydrophobic platform that contains three
exposed aromatic amino acids [10]. In contrast, Type B
CBMs, which bind to single polysaccharide chains, accom-
modate the ligands within extended clefts of varying depths
[10]. In general, the capacity of CBMs to speciﬁcally recog-
nize a range of polysaccharides has been shown to be piv-
otal in a range of biotechnological applications [11].
The development of mechanisms for targeting bio-mol-
ecules to a diversity of matrixes is an emerging theme in
biochemistry and biotechnology. In this work four diﬀerent
AMPs were fused to a family 3 CBM of CipA, a non-
hydrolytic structural protein responsible for the assembly
of Clostridium thermocellum multi-enzyme complex of
cellulases and hemicellulases, termed the cellulosome [12].
The major goal of this approach was not only to promote
the levels of expression of the selected AMPs in E. coli but
also to develop a biotechnological tool that would allow
ﬁxing a variety of polypeptides, such as AMPs, onto
cellulosic surfaces. Therefore, the immobilization of these
fusion proteins in cellulosic supports will allow the
generation of novel bio-products possessing antimicrobial
properties. Cellulose is a safe and inert macromolecule
and has excellent physical properties. In addition, it is
cheap and commercially available in many diﬀerent forms
and has been approved for many pharmaceutical and
human uses [11].1 Abbreviations used: AMPs, antimicrobial peptides; CBMs, carbohy-
drate-binding modules; LK, linker sequence; PCR, polymerase chain
reaction; LB, Luria–Bertani broth; IPTG, isopropyl-b-D-thiogalactopyra-
noside; IMAC, immobilized metal ion aﬃnity chromatography.Materials and methods
Cloning of the DNA sequence of CBM3 with a N-terminal
linker
The gene encoding CBM3 fused to the endogenous
CipA N-terminal linker sequence (LK) was isolated
through PCR. The inclusion of the linker region in the
encoding DNA sequence was envisaged to improve ﬂexibil-
ity in the resulting fusion proteins. The DNA fragment
encoding CBM3 and its N-terminal LK from C. thermocel-
lum was ampliﬁed by polymerase chain reaction (PCR)
from C. thermocellum YS genomic DNA with the thermo-
stable DNA polymerase Pfu Turbo (Stratagene). The prim-
ers used were 50-ACACCGACCAAGGGAGCAACA-30
(forward primer) and 50-TTCTTTACCCCATACAAG
AAC-30 (reverse primer). PCR was performed as follows:
preheating at 95 C for 3 min, 25 cycles at 95 C for 20 s,
55 C for 30 s and 72 C for 30 s, followed by a ﬁnal elon-
gation period at 72 C for 10 min. The ampliﬁed product
was recovered from a 1% agarose gel using the Gel Band
Puriﬁcation Kit (GE Health) and ligated into pMOSBlue
(GE Health) to generate pCG1. The DNA insert of
pCG1 was sequenced to ensure that no mutations had
occurred during the PCR. This plasmid was used as tem-
plate for the subsequent ampliﬁcations aiming at generat-
ing the fusion genes.
Cloning of the DNA sequences encoding the fusion proteins
For these studies four cationic and amphiphilic peptides
were selected: peptide-1 (LKLLKKL), peptide-2 (LKLL
KKLLKLLKKLGGGK), peptide-3 (LKKLLKKLKKL
LKK) and porcine myeloid antibacterial peptide-23
(PMAP-23) (RIIDLLWRVRRPQKPKFVTVWVR) [13],
as depicted in Table 1. The nucleotide sequence of each
peptide was engineered to allow codon optimization in
E. coli. Sequences encoding the four peptides were included
in the primers and fusion genes were generated through
PCR, using the DNA polymerase FideliTaq (GE Health),
utilizing plasmid pCG1 as template. The sequences of the
primers used in this study for this particular aim are shown
in Table 2. Primers included NheI and XhoI restriction
sites. To allow the sub-cloning of the gene encoding
CBM3 fused to the linker sequence (LK-CBM3) into the
expression vector, the DNA sequence encoding this trun-
cated version of CipA was also ampliﬁed by PCR (Table
2). The PCR reactions were performed as follows: preheat-
ing at 95 C for 2 min, 25 cycles at 95 C for 30 s, 55 C for
30 s and 68 C for 1 min, followed by a ﬁnal elongation
period of 68 C for 5 min. Ampliﬁed fragments were recov-
ered from a 1% agarose gel using the Qiagen Gel Extrac-
tion Kit (Qiagen), ligated into plasmid pMOSBlue and
sequenced to ensure that no mutations had occurred during
the PCR. The generated recombinant plasmids were
digested with NheI and XhoI and the excised products
were cloned into expression vector pET21a (Novagen), pre-
Table 1
Primary sequence of antimicrobial peptides used for fusion with a family 3 CBM
Antimicrobial peptide No. of residues Primary sequence References
Peptide-1 7 LKLLKKL
Peptide-2 18 LKLLKKLLKLLKKLGGGK
Peptide-3 14 LKKLLKKLKKLLKK [16]
PMAP-23 23 RIIDLLWRVRRPQKPKFVTVWVR [13]
Table 2
Primers used for cloning the DNA sequences encoding various AMPs in fusion with the gene of a family 3 CBM
Construct Primers Sequence (50–30)
Peptide-1-LK-CBM3 Forward CTCGCTAGCCTGAAACTGCTGAAAAAACTGACACCGACCAAGGGAGCAa
Reverse CACCTCGAGTTCTTTACCCCATACAAGAAC
Peptide-2-LK-CBM3 Forward CTCGCTAGCCTGAAACTGCTGAAAAAACTGCTGAAACTGCTGAAAAAACT
GGGTGGTGGTAAAACACCGACCAAGGGAGCA
Reverse CACCTCGAGTTCTTTACCCCATACAAGAAC
Peptide-3-LK-CBM3 Forward CTCGCTAGCCTGAAAAAACTGCTGAAAAAACTGAAAAAACTGCTGAAAAA
AACACCGACCAAGGGAGCA
Reverse CACCTCGAGTTCTTTACCCCATACAAGAAC
PMAP-23-LK-CBM3 Forward CTCGCTAGCCGTATTATTGATCTGCTGTGGCGTGTGCGTCGTCCGCAGAAA
CCGAAATTTGTGACCGTGTGGGTGCGTACACCGACCAAGGGAGCA
Reverse CACCTCGAGTTCTTTACCCCATACAAGAAC
LK-CBM3 Forward CTCGCTAGCACACCGACCAAGGGAGCA
Reverse CACCTCGAGTTCTTTACCCCATACAAGAAC
a The NheI and XhoI restriction sites introduced in the forward and reverse primers, respectively, are shown in bold.
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vector carries a T7lac promotor and the resulting recombi-
nant proteins contained a C-terminal His6-tag to facilitate
puriﬁcation.Expression of recombinants LK-CBM and fused proteins
To optimize expression of the various recombinant pro-
teins, diﬀerent growing and induction conditions were
tested for a variety of recombinant E. coli strains. Below
is a description of the optimized growing conditions
obtained that allow the expression of each speciﬁc protein.
To express peptide-1 fused to LK-CBM3 (peptide-1-LK-
CBM3) and peptide-3 fused to LK-CBM3 (peptide-3-LK-
CBM3), E. coli Tuner (DE3) (Novagen) cells harboring
the appropriate recombinant plasmids were cultured in
Luria–Bertani broth (LB) containing 100 lg/mL ampicillin
at 37 C to mid-exponential phase (OD595 = 0.6). At this
point isopropyl-b-D-thiogalactopyranoside (IPTG) was
added to a ﬁnal concentration of 0.2 mM and the cultures
were incubated at 18 C and 30 C for 16 h, respectively.
The proteins LK-CBM3 and PMAP-23-LK-CBM3, which
results from the fusion of LK-CBM3 with PMAP-23, were
expressed in E. coli BL21 (DE3) (Novagen) cells harboring
the appropriate recombinant plasmids and cultured in LB
containing 100 lg/mL ampicillin at 37 C to mid-exponen-
tial phase (OD595 = 0.6). At this point IPTG was added to
a ﬁnal concentration of 1 mM and the cultures were incu-
bated at 37 C for further 4 h. Peptide-2 in fusion withLK-CBM3 (peptide-2-LK-CBM3) was found to be insolu-
ble when expressed by diﬀerent E. coli strains under a range
of induction conditions, which included inducing tempera-
tures varying from 16 C to 37 C and IPTG concentra-
tions ranging from 0.01 mM to 1 mM.Puriﬁcation of recombinant proteins
Recombinant E. coli cells were harvested by centrifuga-
tion at 7000g at 4 C for 15 min, resuspended in 20 mM
Tris–HCl pH 7.0, 20 mM NaCl, 5 mM CaCl2 (2H2O) (Buf-
fer A) and disrupted by sonication on ice for 12 min. The
resulting cell-free extracts were collected by centrifugation
at 20,440g at 4 C for 30 min and the His6-tagged recombi-
nant proteins puriﬁed by immobilized metal ion aﬃnity
chromatography (IMAC), using 5 mL Niquel Hi-Trap Col-
umns (GE Health). The column charged with 0.1 M NiSO4
was equilibrated with 20 mM Na3PO4, 500 mM NaCl,
40 mM Imidazole, pH 7.4. The cell extracts were loaded
into the column which was washed with the equilibration
buﬀer. Finally the recombinant proteins were eluted with
20 mM Na3PO4, 500 mM NaCl, 300 mM Imidazole, pH
7.4. After puriﬁcation, proteins buﬀer were exchanged into
Buﬀer A, using PD10-columns (GE Health). Puriﬁed pro-
teins were analyzed by mass spectrometry and SDS–PAGE
using 12% (w/v) acrylamide gels. Predicted sizes for the
recombinant proteins were 22.1 kDa for LK-CBM3,
23.0 kDa for peptide-1-LK-CBM3, 24.1 kDa for peptide-
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25.1 kDa for PMAP-23-LK-CBM3.
Binding assays
Qualitative assessment of the binding of the recombi-
nant proteins to Avicel (Sigma) was developed as follows:
100 lg of LK-CBM3, 50 lg of peptide-1-LK-CBM3,
50 lg of peptide-3-LK-CBM3 and 50 lg of PMAP-23-
LK-CBM3, all in Buﬀer A, with 1% (v/v) Tween 20, were
mixed with 4 mg of Avicel in a ﬁnal reaction volume of
200 lL. The mixture was incubated for 1 h at 30 C with
vigorous shaking. The insoluble ligand was collected by
centrifugation at 13,000g at room temperature for
10 min. The supernatant, containing the unbound fraction,
was recovered and the resulting pellet was washed four
times with 400 lL Buﬀer A and 20 lL 1% (v/v) Tween
20. Finally the carbohydrate pellet was resuspended in
100 lL 10% (w/v) SDS and 25 lL 5 SDS sample buﬀer.
Bound and unbound fractions were analyzed by SDS–
PAGE using a 12% (w/v) acrylamide gel. Controls contain-
ing protein but no polysaccharide were performed in parallel
to ensure that no precipitation of the recombinant proteins
occurred during the experiment (data not shown).
Antimicrobial assay
An antimicrobial assay for assessing the antibacterial
properties of LK-CBM3was implemented based on the pro-
cedures described in reference [14]. Brieﬂy, 100 mL of LB
were inoculated with colonies from an overnight culture
plate of E. coli XL10 Gold (Stratagene) and grown at
37 C until OD600 = 0.5. The cells (1 mL) were recovered
by centrifugation at 3000g at 10 C for 10 min and the super-
natant discarded. Cells were washed twice with 1 mL of Buf-
ferA. Finally, bacteriawere resuspended in 1 mLof the same
buﬀer and serially diluted until 104. Precisely 150 lL of
E. coli XL10 Gold 104 were incubated with 150 lL LK-
CBM3 at three diﬀerent protein concentrations (0.1 mg/
mL, 1 mg/mL, and 2 mg/mL, all diluted in BuﬀerA). Several
controls were incorporated in the experiment, including the
incubation of the cells solely in Buﬀer A or with BSA at theFig. 1. Expression of the recombinant proteins LK-CBM3 (A), peptide-1-LK-C
23-LK-CBM3 (E). Lanes: 1, uninduced cells; 2, cells induced with IPTG; St, m
from the resuspention of the bacterial cells in Buﬀer A. Arrows highlight thesame protein concentrations used for LK-CBM3. Cells were
incubated under the various conditions at 210 rpm in an
orbital incubator at 37 C for 2 h. At the end of the incuba-
tion period, 50 lL of each sample were plated onto LB agar
plates and the number of bacterial colonies formed was
counted after a 16 h incubation at 37 C. The remaining of
the non-plated mixture was centrifuged at 13,000g at 4 C
for 5 min and the supernatants used for protein quantitation
using Bradford reagent [15] and analyzed by SDS–PAGE
using a 14% (w/v) acrylamide gel.
Results and discussion
Expression and puriﬁcation of recombinant LK-CBM and
fused proteins
Four peptides, termed peptide-1, peptide-2, peptide-3 and
PMAP-23 [13], which details are presented in Table 1, were
fused with the family 3 CBM of CipA from C. thermocel-
lum. The recombinant fusion proteins were engineered to
contain an N-terminal AMP domain and a C-terminal
His6-tag. Peptide-1, peptide-2, and peptide-3 are synthetic
amphiphilic cationic peptides, which design was based on
the studies provided by other authors [16,17]. Similar
molecules have already proved to have potent antimicro-
bial activity against Gram negative and Gram positive
bacteria [16]. It has also been previously shown that
peptides composed of both hydrophobic and hydrophilic
residues, such as leucine (L) and lysine (K), present antimi-
crobial activity against E. coli and Staphylococcus aureus,
both in the soluble form or immobilized into a water-insol-
uble non-degradable polymer support [17]. These appar-
ently simple cationic peptides with proven detectable
antimicrobial activity were selected to fuse with CtCBM3.
In addition, a diﬀerent peptide with antimicrobial activity,
termed PMAP-23, was also selected for fusion with the
carbohydrate-binding module [13]. This peptide derives
from porcine myeloid cells, is highly cationic and also tends
to form an amphipathic structure, typical of other antibac-
terial peptides [1]. Synthetic PMAP-23 showed antibacte-
rial activity against Gram positive and negative strains
but no lytic activity against human erythrocytes, whichBM3 (B), peptide-2-LK-CBM3 (C), peptide-3-LK-CBM3 (D) and PMAP
olecular mass protein standards. Protein extracts of Lanes 1 and 2 resul
position of each one of the recombinant proteins.-
t
C.I.P.D. Guerreiro et al. / Protein Expression and Puriﬁcation 59 (2008) 161–168 165suggested a certain degree of selectivity in disrupting cell
membranes [1,13]. It has been suggested that PMAP-23
antibacterial activity results from the interaction of the
peptide with the bacteria cell membrane, followed by bac-
teria membrane alteration [1,13].
Data presented in Fig. 1 conﬁrms that all four recombi-
nant fusion proteins were expressed in E. coli. However,
only peptide-1-LK-CBM3, peptide-3-LK-CBM3, PMAP-
23-LK-CBM3 and LK-CBM3 were expressed in the solu-Fig. 2. Expression of recombinant peptide-2-LK-CBM3 in diﬀerent E. col
strains grown under diﬀerent growth and induction temperatures. (A
E. coli Tuner (lanes 1–3) and BL21 (DE3)pLysS (lanes 4–6) grown a
30 C, induced at 30 C. (B) BL21 (DE3)pLysS grown at 37 C, induced a
18 C (lanes 1–3) and at 30 C (lanes 4–6). Lanes 1 and 4, cells induced
with IPTG; lanes 2 and 5, soluble cell-free extract; lanes 3 and 6, insoluble
cell pellet; St, molecular mass protein standards.
Fig. 3. Comparing the expression and solubility of recombinant peptide-2
peptide-1-LK-CBM3 (lanes 1–3) and peptide-2-LK-CBM3 (lanes 4–6) in
(lanes 4–6) induced at 30 C. Lanes 1 and 4, cells induced with IPTG;
molecular mass protein standards.i
)
t
t-LK-C
duced
lanesble fraction of E. coli, although as a result of several opti-
mization experiments (results not shown). In contrast, pep-
tide-2-LK-CBM3 formed inclusion bodies in E. coli and
protein precipitation in vivo was persistent while using dif-
ferent E. coli expression strains and diﬀerent growth and
induction temperatures (Figs. 2 and 3). To overcome the
insolubility of some AMPs, as well as their cytotoxic prop-
erties, some authors expressed these peptides in E. coli in
fusion with diﬀerent protein partners, utilizing diﬀerent
expression systems. Therefore, SMAP-29 was expressed
using the intein-mediated system [14], the human b-defen-
sin 2 with the thioredoxin expression system [3,6], Hal18
by fusion with baculoviral polyhedron protein [9] and
LL-37 utilizing the glutathione. S-transferase fusion system
[7], among many other examples. In addition, enterocins A
and B, which are bacteriocins from Enterococcus faecium,
were produced in fusion with a microbial CBM, although
the experiment aimed at developing an easier puriﬁcation
system for the recombinant proteins [18]. In general, the
aim of these experiments was to develop a mechanism to
produce at high levels the fusion protein in order to
enhance the production of the AMP itself. Therefore, after
puriﬁcation of the fused proteins, a proteolytic digestion
step using a speciﬁc protease is included in order to release
the AMP in the puriﬁed form. In contrast with the above
mentioned experiments, the aim of the work reported here
was to obtain the AMPs fused with CtCBM3 as the ﬁnal
product. More than a mere fusion partner, CBM3 was used
to target the AMP for cellulosic surfaces. Notwithstanding
this major goal of the experiments, it can be anticipated
that the expression and puriﬁcation of the AMP fusion
recombinant proteins was probably facilitated by the pres-
ence of CBM3 and the C-terminal His6-tag.
After optimizing expression in E. coli, the recombinant
proteins were puriﬁed through IMAC. The data, presented
in Fig. 4, demonstrate that all proteins were puriﬁed from
mostE. coli contaminants andwere obtained at high concen-
trations. Following the puriﬁcation step, the proteins were
buﬀer exchanged into Buﬀer A and their concentration cal-
culated. Puriﬁed proteins presented ﬁnal concentrationsBM3 with two other recombinant proteins expressed in E. coli Tuner. (A)
at 18 C. (B) peptide-3-LK-CBM3 (lanes 1–3) and peptide-2-LK-CBM3
2 and 5, soluble cell-free extract; lanes 3 and 6, insoluble cell pellet; St,
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analysis conﬁrmed the expected sizes and, therefore, the
integrity of the four recombinant proteins, suggesting that
the N-terminal AMP domain was not subjected to proteoly-
sis in E. coli and during the puriﬁcation steps.
Binding assays
CtCBM3 fromCipA is a verywell characterized and stud-
ied CBM [11,12] and its three-dimensional structure has
already been elucidated [12]. It is a Type A CBM, which
means that it possesses a planar surface that interacts tightly
with crystalline cellulose. CtCBM3 equilibrium aﬃnity con-
stant (Ka) for Avicel was reported to be 7.7  106 M1 [11].
To investigate whether the fusion of each of the four AMPs
to CtCBM3 had some eﬀect on its capacity to interact with
crystalline cellulose, the capacity of the recombinant pro-
teins to bind Avicel was evaluated. The data, presented in
Fig. 5, conﬁrmed that all AMPs-LK-CBM3 retained capac-
ity to bind Avicel, as revealed by the minor quantity of pro-
tein present in the unbound fraction and the resulting
association of the recombinant protein with the carbohy-
drate fraction. Although a small quantity of LK-CBM3
was shown not to bind the structural carbohydrate (panel
A, lane U), this phenomenon is certainly due to a relative
excess of protein concentration in relation to the Avicel. In
addition, the data also suggested that incorporation ofFig. 4. Puriﬁcation of the recombinant proteins LK-CBM3 (A), peptide-1-LK
aﬃnity chromatography. Lanes: 1, soluble cell-free extract; 2, insoluble cell
molecular mass protein standards.His6-tag in the recombinant proteins had no eﬀect in the
capacity of the protein to bind cellulose. Taken together
the results suggest that fusion of CBM3 with AMPs had no
aﬀect in cellulose-binding activity of the CBM, which makes
the recombinant proteins potential candidates to target
AMPs to cellulosic supports.
Evaluating the antimicrobial activity of CBM3
It has been reported that C-type lectins, another kind
of carbohydrate-binding molecules, may present antimi-
crobial activity [19,20]. Like CBMs, lectins are proteins
that recognize carbohydrates and fulﬁll an important role
in the immune system, which has been extensively studied
over the last years. Lectins are well described but the
understanding of the mechanisms by which they inﬂuence
the immune responses is not well deﬁned. However, it is
believed that lectins are involved in the recognition of car-
bohydrates at cell surfaces [21]. To ﬁnd out whether the
recombinant LK-CBM3 itself would present antibacterial
activity, an assay was performed against E. coli XL10
Gold cells (Stratagene). BSA was incorporated in this
experiment as a control protein which does not possess
recognizable antimicrobial activity. Both proteins were
used at three diﬀerent concentrations: 0.1 mg/mL, 1 mg/
mL, and 2 mg/mL. The data, presented in Table 3, dem-
onstrated that the numbers of CFU/mL are in the same-CBM3 (B), peptide-3-LK-CBM3 (C) and PMAP-23-LK-CBM3 (D) by
pellet; 3, column ﬁltrate; 4–6, column washes; 7 and 8, pure protein; St,
Fig. 5. Binding of LK-CBM3 (A), peptide-1-LK-CBM3 (B), peptide-3-LK-CBM3 (C) and PMAP-23-LK-CBM3 (D) to Avicel. Lanes: P, puriﬁed protein
used in the experiment; U, unbound protein; W1, W2, W3 and W4, wash fractions; B, bound protein.
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and had no variation when compared with the numbers of
CFU following incubation with Buﬀer A. Therefore, the
results suggest that LK-CBM3 did not aﬀect the number
of existing bacteria, conﬁrming that this CBM does not
present an antibacterial activity, in contrast to what has
been described for C-type lectins [19,20]. This observation
is not particularly surprising in light of our present
knowledge on the structure of Type A CBMs. It is well
established that CtCBM3 has a ligand binding speciﬁcity
restricted for crystalline cellulose. In addition, its planar
binding surface is not eﬀective for interacting with indi-
vidual carbohydrate chains that are usually present onTable 3
Antimicrobial activity of LK-CBM3
Protein concentration
(mg/mL)
Proteins
LK-CBM3
(102 CFU/mL)
BSA
(102 CFU/mL)
0.1 7 4
1 7 9
2 3 9
Escherichia coli XL10 Gold was incubated with LK-CBM3 and BSA at
three diﬀerent concentrations and then plated onto LB agar plates. CFU/
mL were calculated after a 16 h incubation at 37 C. The number of CFU/
mL for the experiment using exclusively buﬀer was 8  102. The values are
average of three replicates.
Table 4
Interaction of LK-CBM3 and BSA with E. coli XL10 Gold
Initial protein (mg/mL) Unbound protein (mg/mL)
A B C D
0.1 0.1 0.1 0.1 0.1
1 0.8 0.8 0.7 0.7
2 1.2 1.2 1.2 1.2
LK-CBM3 and BSA were incubated with E. coli XL10 Gold and cell
bound protein evaluated by measuring protein concentration on the
supernatant. A, E. coli with LK-CBM3; B, Buﬀer A with LK-CBM3; C,
E. coli with BSA and D, Buﬀer A with BSA.the microorganisms’ surface glycoproteins, as lectins do.
Therefore, structural constrains would preclude the inter-
action of the family 3 CBM with the bacterial cell surface.
To conﬁrm the inability of CBM3 to interact with the
bacterial surface, LK-CBM3 and BSA were incubated
with E. coli cells and bound protein was detected follow-
ing cell centrifugation through the measuring of protein
concentration in the supernatant. The data, presented in
Table 4, conﬁrms that the two proteins have no capacity
to attach to the bacteria surface since the concentration of
LK-CBM3 recovered by centrifugation after incubation
with bacteria equals the one recovered after the same
incubation with Buﬀer A, for all initial protein concentra-
tions (0.1 mg/mL, 1 mg/mL and 2 mg/mL). A similar
result was observed for BSA incubation with E. coli
XL10 Gold and Buﬀer A (columns C and D from Table
4). Although a small quantity of protein was lost from the
initial concentration (for the protein concentrations of
1 mg/mL and 2 mg/mL), this was probably due to protein
precipitation during the assays as it was also observed for
the incubation with Buﬀer A. The supernatants used for
protein quantitations were also analyzed by SDS–PAGE.
The data, presented in Fig. 6, conﬁrmed that lack of bind-
ing was not associated with LK-CBM3 (lanes 1–3) and
BSA (lanes 4–6) proteolytic degradation.Conclusions
Here four AMPs were cloned and expressed in fusion
with a family 3 CBM of C. thermocellum cellulosome.
Expression occurred in the soluble form for three recombi-
nants and protocols for purifying the recombinant proteins
by IMAC were developed. CtCBM3 does not present
detectable antimicrobial activity against E. coli XL10
Gold. Therefore, CBM3 is a good candidate polypeptide
to direct binding of AMPs to cellulosic supports. Data pre-
sented here conﬁrm that the fusion recombinants are now
ready for further studies to measure and characterize their
antimicrobial properties. Here it was shown that CBM3
may be attached to a non-related protein retaining its
Fig. 6. Binding of LK-CBM3 and BSA into E. coli XL10 Gold as judged
by SDS 14% acrylamide gel analysis. Lanes: 1, LK-CBM3 0.1 mg/mL; 2,
LK-CBM3 1 mg/mL; 3, LK-CBM3 2 mg/mL; 4, BSA 0.1 mg/mL; 5, BSA
1 mg/mL; 6, BSA 2 mg/mL, St, molecular mass protein standards.
168 C.I.P.D. Guerreiro et al. / Protein Expression and Puriﬁcation 59 (2008) 161–168intrinsic biological activity [11]. It has also been conﬁrmed
that AMPs produced in E. coli fused to a CBM maintained
their properties after puriﬁcation and separation from the
fusion partner [18]. Therefore, the perspectives that the
fusion proteins obtained in this work can display intrinsic
antimicrobial activity are good and it is anticipated that
their antimicrobial potency should be comparable to the
AMPs expressed individually. Further studies will proceed
in the future aiming at quantifying the antimicrobial prop-
erties of the proteins reported here, both in solution or
ﬁxed into insoluble surfaces.
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